Antares Pharma, Inc. (AIS) Reports In-Line Q3 EPS Loss of $0.01

Antares Pharma, Inc. (NYSE: AIS) reported Q3 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $3.85 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c